iShares US Pharmaceuticals ETF
95 hedge funds and large institutions have $133M invested in iShares US Pharmaceuticals ETF in 2018 Q2 according to their latest regulatory filings, with 9 funds opening new positions, 10 increasing their positions, 43 reducing their positions, and 15 closing their positions.
283% more call options, than puts
Call options by funds: $4.53M | Put options by funds: $1.18M
4.5% more ownership
Funds ownership: 106.78% → 111.28% (+4.5%)
4% less capital invested
Capital invested by funds: $139M → $133M (-$5.77M)
6% less funds holding
Funds holding: 101 → 95 (-6)
40% less first-time investments, than exits
New positions opened: 9 | Existing positions closed: 15
77% less repeat investments, than reductions
Existing positions increased: 10 | Existing positions reduced: 43
100% less funds holding in top 10
Funds holding in top 10: 1 → 0 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CWM
Cornerstone Wealth Management
St. Peters,
Missouri
|
+$3.82M |
| 2 |
KCM
Karp Capital Management
Sausalito,
California
|
+$2.62M |
| 3 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$2.47M |
| 4 |
Morgan Stanley
New York
|
+$2.01M |
| 5 |
MGIA
Matthew Goff Investment Advisor
Houston,
Texas
|
+$860K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Bank of America
Charlotte,
North Carolina
|
-$4.22M |
| 2 |
AWA
ARS Wealth Advisors
St. Petersburg,
Florida
|
-$3.09M |
| 3 |
UBS Group
Zurich,
Switzerland
|
-$2.79M |
| 4 |
Royal Bank of Canada
Toronto,
Ontario, Canada
|
-$1.16M |
| 5 |
Citadel Advisors
Miami,
Florida
|
-$989K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
101
CIBC World Market
Toronto,
Ontario, Canada
| – | -$229K | -4,650 | Closed |
|
|
EFS
102
Essex Financial Services
Essex,
Connecticut
| – | -$207K | -4,200 | Closed |
|
|
AFC
103
AFT Forsyth & Company
West Palm Beach,
Florida
| – | -$205K | -4,161 | Closed |
|
|
IWM
104
IHT Wealth Management
Chicago,
Illinois
| – | -$76K | -1,617 | Closed |
|
|
ADL
105
Asset Dedication LLC
San Francisco,
California
| – | -$79K | -1,605 | Closed |
|
|
CPA
106
Clear Perspective Advisors
Aurora,
Illinois
| – | -$52K | -1,050 | Closed |
|
|
WAS
107
WESPAC Advisors SoCal
Pasadena,
California
| – | -$31K | -636 | Closed |
|
|
CDIA
108
Capital Directions Investment Advisors
Atlanta,
Georgia
| – | -$15K | -300 | Closed |
|
|
MA
109
MCF Advisors
Covington,
Kentucky
| – | -$2K | -42 | Closed |
|
IHE Hedge Fund Activity: Q2 2018 in Review
95 of the 4,368 institutional investors tracked by Wall St. Rank reported a position in iShares US Pharmaceuticals ETF (IHE) for Q2 2018, worth a combined $133M — down 4.1% from $139M a quarter earlier.
Sellers outnumbered buyers: 15 funds closed out of IHE and 9 opened new positions — a net loss of 6 holders — while 43 trimmed existing stakes and 10 added.
The largest buyer was Cornerstone Wealth Management, opening a new position worth an estimated $3.82M. The largest seller was Bank of America, cutting an estimated $4.22M.
- 95 institutional investors held iShares US Pharmaceuticals ETF (IHE) as of Q2 2018, down from 101 in Q1 2018.
- Funds reported $133M of iShares US Pharmaceuticals ETF stock for Q2 2018, down 4.1% quarter-over-quarter.
- 9 funds opened new iShares US Pharmaceuticals ETF positions in Q2 2018 and 15 closed out, a net change of -6 holders.
- The largest iShares US Pharmaceuticals ETF buyer in Q2 2018 was Cornerstone Wealth Management, an estimated $3.82M added.
- The largest iShares US Pharmaceuticals ETF seller in Q2 2018 was Bank of America, an estimated $4.22M sold.
Based on aggregated 13F filings for Q2 2018.